HCV Treatment
IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa
- Details
- Category: HCV Treatment
- Published on Friday, 28 July 2017 00:00
- Written by Liz Highleyman
Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.
FDA Approves Gilead's Vosevi Combo Pill for Hepatitis C Re-treatment
- Details
- Category: Approved HCV Drugs
- Published on Tuesday, 18 July 2017 00:00
- Written by Liz Highleyman
On July 18, the U.S. Food and Drug Administration(FDA) approved Gilead Sciences' Vosevi, a new once-daily combination pill containing sofosbuvir, velpatasvir, and voxilaprevir. Vosevi was approved as "salvage therapy" for people with all hepatitis C virus (HCV) genotypes who were not previously cured with prior direct-acting antiviral therapy.
Coverage of the 2017 Harm Reduction International Conference
- Details
- Category: HIV Treatment
- Published on Wednesday, 31 May 2017 00:00
- Written by HIVandHepatitis.com
HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.
5/31/17
HR17: Indonesian Buyers Club Helps People Obtain Generic Hepatitis C Treatment
- Details
- Category: HCV Treatment
- Published on Wednesday, 31 May 2017 00:00
- Written by Liz Highleyman
A community-led buyers club in Indonesia has helped more than 100 people get generic direct-acting antiviral drugs to treat hepatitis C and is seeing a high cure rate, according to a presentation at the 25th Harm Reduction International Conference this month in Montreal.
HR17: Hepatitis C Virus Reinfection Is Uncommon After Being Cured with DAAs
- Details
- Category: HCV Treatment
- Published on Thursday, 18 May 2017 00:00
- Written by Liz Highleyman
Most people on opiate substitution therapy were successfully treated for hepatitis C with an interferon-free regimen of grazoprevir/elbasvir (Zepatier), and only a small number became reinfected during 3 years of follow-up, researchers reported at the 25th Harm Reduction International Conference this week in Montreal.
More Articles...
- EASL 2017: Triple Combination Cures Most Hepatitis C Patients with Prior DAA Failure
- EASL 2017: Generic Hepatitis C Drugs Continue to Produce High Cure Rates
- EASL 2017: New AbbVie Hepatitis C Combination Cures 99% of People with Cirrhosis
- EASL 2017: Children with Hepatitis C Respond Well to Sofosbuvir/Ledipasvir
Web Design and Development by